Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al.
The recently published article by Kobashigawa et al. [1] regarding the benefit of using pravastatin in treating hypercholesterolemia in heart transplant recipients is reviewed. A comment on the implications of the researchers' findings follows.
Gotto
A M
AM
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control; D003331:Coronary Vessels / Q000473:pathology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation / Q000401:mortality; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008297:Male; D017035:Pravastatin / Q000627:therapeutic use*; D011446:Prospective Studies
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D017035:Pravastatin